AI Article Synopsis
- Four cases of high-risk metastatic castration-sensitive prostate cancer (mCSPC) were treated with abiraterone, showing a strong, sustained response lasting over 5 years.
- * Immunohistochemical analysis revealed that all cancer tissues from these cases were negative for AKR1C3, a marker associated with poor prognosis in advanced prostate cancer.
- * This study is the first to link negative AKR1C3 expression in high-risk mCSPC with positive responses to abiraterone treatment.
Article Abstract
We experienced four cases of high-risk metastatic castration-sensitive prostate cancer (mCSPC) in which first-line treatment with abiraterone showed a sustained long-term response of over 5 years. We conducted immunohistochemical staining of aldo-keto reductase family 1 member C3 (AKR1C3) expression, which associate with poor prognosis of metastatic castration-resistant prostate cancer (mCRPC), and all prostate cancer tissue from four cases showed negative. These results suggested that AKR1C3-negative high-risk mCSPC cases may respond well to first-line treatment with abiraterone. This is the first report describing association of high-risk mCSPC and negative AKR1C3.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11015377 | PMC |
| http://dx.doi.org/10.1016/j.eucr.2024.102727 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!